Benchmark has secured an exclusive worldwide license from Saiba Animal Health GmbH, to develop and commercialise a recombinant vaccine for Canine Atopic Dermatitis (CAD) using Virus Like-Particle (VLP) technology.
- Saiba Animal Health AG selected to present at the 6th Annual Animal Health, Nutrition and Technology Innovation Forum, USA.
- Saiba Animal Health AG’s executes a license for the development and commercialization of a lead product candidate.
- Saiba Animal Health AG Signs Second Agreement with Boehringer Ingelheim
- Saiba Animal Health AG signs a deal to test and develop another product candidate from its pipeline
- Saiba Animal Health AG has a new development partner for its two lead projects